Fig. 4.

Various HLA molecules present immunodominant NP peptides. (A) The 13mer peptides within the NP209–237 18mers (donor 2) were screened, with the 18mer results being shown as open bars (i). Three 13mer overlapping peptides were titrated to compare their activity (ii), and HLA-matched BLCLs were used to identify the HLA presenting the NP219–231 13mer (iii and iv). (B) The 13mer peptides within NP133–150 (donor 4) were screened as in A (B, i). The minimal NP_140–150 peptide and its amino acid-truncated and -extended variants were tested under serum-free conditions (ii), and the HLA restriction profile for NP_140–150 was determined using HLA matched BLCLs (iii, iv). (C) The 13mer peptides within the NP331–348 18mer (donor 5) were screened as in A (C, i). Four 13mers were titrated to determine their activity (ii); single amino acid-truncated and -extended peptides of NP_336–344 were tested under serum-free conditions (iii), and the HLA restrictions of 13mer containing NP_336–344 were analyzed as in A (iii and iv).